Jaktinib
Jaktinib is approved in at least one market for alopecia areata, developed by Suzhou Zelgen Biopharmaceuticals.
A Chinese JAK inhibitor, gecacitinib, approved in China for severe alopecia areata in June 2026 as a tablet, with a cream that stalled at Phase 1/2.
- Developed by
- Suzhou Zelgen Biopharmaceuticals
- Current phase
- Approved
- Mechanism
- JAK inhibitor
- Indications
- Alopecia areata
- Also known as
- jaktinib hydrochloride, gecacitinib, gecacitinib hydrochloride, ZG0244, Zepuping
- Last public activity
- March 2025
- Copy last reviewed
- September 2026
- Record confidence
- High
Cleared for sale for a hair-loss indication in at least one market.
Calms the immune attack on the follicle by blocking JAK signalling - the class that transformed alopecia areata.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
How it is meant to work
A JAK inhibitor developed by Zelgen under the names jaktinib and, since its approval, gecacitinib, registered in alopecia areata both orally and as a topical cream. Running the same molecule by both routes tests whether a topical can reach the follicle, the question that sank delgocitinib and ATI-50002; the cream's Phase 1/2 has not been updated since March 2024.
Why it matters
It is the register's clearest case of a programme that is well advanced and almost invisible in English. The tablet was approved in China for myelofibrosis in May 2025 and, on 15 June 2026, for severe alopecia areata in adults, on a completed 425-patient Phase 3 across 44 hospitals in which, by Zelgen's account, 34.5% of patients on 50 mg reached a SALT score of 20 or below at week 24 against 3.5% on placebo. Little of this appears in Western coverage, so this row exists mainly so the history is findable at all.
Where it is approved
Marketing authorisation is granted country by country, for a specific indication. A drug approved for hair loss in one market may be approved only for something else — or not at all — in another.
- ChinaNMPAApproved· prescription only
Severe alopecia areata in adults
Marketing approval announced by Zelgen on 15 June 2026 for gecacitinib hydrochloride tablets (formerly jaktinib); the tablet was approved for myelofibrosis in May 2025.
Regulator filing ↗
Development history
- Phase 2Phase 3
First Phase 3 trial on record: NCT05051761 — Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
ClinicalTrials.gov ↗ - Phase 2
First Phase 2 trial on record: NCT04034134 — Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · n=315 · March 2022
Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · n=425 · September 2021
A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · n=160 · August 2020
Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · n=111 · November 2019
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata — ClinicalTrials.gov
- A Study With Jaktinib Hydrochloride Cream Applied Topically — ClinicalTrials.gov
- Zelgen: marketing approval of gecacitinib hydrochloride tablets for severe alopecia areata in adults (盐酸吉卡昔替尼片) — Company release, June 2026
- Development trends of JAK inhibitors over three decades (jaktinib, Zepuping, approved in China for myelofibrosis on 27 May 2025) — Peer-reviewed, May 2026
- Zelgen: NMPA acceptance of the alopecia areata NDA for jaktinib hydrochloride tablets — Company release, May 2025
Related programmes
Other programmes in the register with the same mechanism: JAK inhibitor.
Cite this page
Hair Pipeline, "Jaktinib — development record", hairpipeline.com/pipeline/jaktinib